Rapid progression of familial amyloidotic polyneuropathy: A multinational natural history study

Neurology

Volumn 85, Issue 8, 2015, Pages 675-682

  Adams, David ^a   Coelho, Teresa ^b   Obici, Laura ^c   Merlini, Giampaolo ^c   Mincheva, Zoia ^a   Suanprasert, Narupat ^d   Bettencourt, Brian R ^e   Gollob, Jared A ^e   Gandhi, Pritesh J ^e   Litchy, William J ^d   Dyck, Peter J ^d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c UNIVERSITY OF PAVIA   (Italy)

^d MAYO CLINIC   (United States)

^e ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FRANCE; GENETIC VARIABILITY; GENOTYPE; GRIP STRENGTH; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; NEUROPATHY IMPAIRMENT SCORE; ONSET AGE; POLYNEUROPATHY DISABILITY SCORE; PORTUGAL; PRIORITY JOURNAL; UNITED STATES; AMYLOID NEUROPATHIES, FAMILIAL; CLINICAL TRIAL; GENETICS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGE OF ONSET; AGED; AMYLOID NEUROPATHIES, FAMILIAL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; HUMANS; ITALY; MALE; MIDDLE AGED; PORTUGAL; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84940041748     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001870     Document Type: Article

References (36)

1. Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC. Rate of progression of transthyretin amyloidosis. Am J Cardiol 2011;108:285-289.
2. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88-93.
3. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274:1637-1650.
4. Saraiva MJ, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984;74:104-119.
5. Saraiva MJ, Magalhaes J, Ferreira N, Almeida MR. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem 2012;19:2304-2311.
6. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-184.
7. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010;17:63-68.
8. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274:702-706.
9. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003;28:438-442.
10. Coelho T, Maurer MS, Suhr OB. THAOS-The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63-76.
11. Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007;35:116-118.
12. Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuropathy. Intern Med 1993;32: 920-922.
13. Adams D, Lozeron P, Theaudin M, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012;19(suppl 1):61-64.
14. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-792.
15. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658-2667.
16. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-239.
17. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-482.
18. Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS17 for therapeutic trials. J Neurol Sci 2014;344:121-128.
19. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136-141.
20. Dyck PJ, Herrmann DN, Staff NP, Dyck PJ. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes 2013;62:3677-3686.
21. Dyck PJ, Overland CJ, Low PA, et al. "Unequivocally abnormal" vs "usual" signs and symptoms for proficient diagnosis of diabetic polyneuropathy: Cl vs N Phys Trial. Arch Neurol 2012;69:1609-1614.
22. Dyck PJ, Argyros B, Russell JW, et al. Multicenter trial of the proficiency of smart quantitative sensation tests. Muscle Nerve 2014;49:645-653.
23. Litchy WJ, Albers JW, Wolfe J, et al. Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4). Muscle Nerve 2014;50:900-908.
24. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42:157-164.
25. Dyck PJ, Albers JW, Wolfe J, et al. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve 2013;48:369-374.
26. Easton DM. Gompertzian growth and decay: a powerful descriptive tool for neuroscience. Physiol Behav 2005;86: 407-414.
27. Adams D, Coelho T, Obici L, et al. Neuropathy progression rate in patients with familial amyloidotic polyneuropathy. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27-May 1, 2014; Indianapolis, IN.
28. European Medicines Agency. Assessment Report: Vyndaqel-Tafamidis Meglumine. Report no. EMA/729083/2011 [online]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/002294/human-med-001498.jsp&mid5WC0b01ac058001d124. Accessed December 17, 2014.
29. Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013;6:1011-1020.
30. Alnylam Pharmaceuticals. A phase 3 multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ALN-TTR02 in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy-FAP). Available at: http://clinicaltrials.gov/ct2/show/NCT01960348. Accessed December 17, 2014.
31. Isis Pharmaceuticals. A phase 2/3 randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of ISIS 420915 in patients with familial amyloid polyneuropathy. Available at: http://clinicaltrials.gov/ct2/show/NCT01737398. Accessed December 17, 2014.
32. Lane T, Bangova A, Fontana M, et al. TRANSCEND-(transthyretin amyloidosis: neuropathy, senility, cardiomyopathy; evaluation, natural history and diagnosis)-a comprehensive observational study of transthyretin amyloidosis. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27-May 1, 2014; Indianapolis, IN.
33. Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013;29:77-84.
34. Rapezzi C, Karayal ON, Stewart M, Mundayat R, Suhr O. Markers of disease progression in transthyretin-related amyloidosis identified from a cross-sectional analysis of the THAOS registry. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27-May 1, 2014; Indianapolis, IN.
35. Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012;83:152-158.
36. Dohrn MF, Rocken C, De Bleecker JL, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013; 260:3093-3108.